TRAX First Tracks Biotherapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2091349 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets11.4%
Debt / equity0.00x
Current ratio9.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| R&D expense | $23.85M | $25.64M | $33.95M | $33.32M | $39.27M | $41.47M |
| SG&A expense | $9.00M | $9.29M | $18.86M | $11.73M | $6.63M | $9.81M |
| Operating income | -$32.84M | -$34.94M | -$52.81M | -$45.06M | -$45.90M | -$51.28M |
| Net income | -$31.36M | -$33.37M | -$50.48M | -$41.86M | -$42.45M | -$47.20M |
| EBITDA | -$32.75M | -$34.83M | -$52.69M | -$44.92M | -$45.76M | -$51.13M |
| EPS (basic) | -0.88 | -0.95 | — | -1.50 | -1.47 | — |
| EPS (diluted) | -0.88 | -0.95 | — | -1.50 | -1.47 | — |
| Weighted avg. shares (diluted) | 35.75M | 35.00M | — | 27.83M | 28.81M | — |
| Balance sheet | ||||||
| Cash & equivalents | $155.63M | $168.02M | $248.47M | $109.83M | $44.30M | $98.64M |
| Short-term investments | $0 | $0 | $37.99M | — | — | — |
| Current assets | $165.72M | $177.75M | $289.40M | — | — | — |
| PP&E, net | $979,000 | $1.07M | $1.17M | — | — | — |
| Total assets | $170.46M | $183.14M | $290.58M | — | — | — |
| Current liabilities | $18.09M | $12.45M | $33.11M | — | — | — |
| Total liabilities | $19.45M | $14.34M | $33.11M | — | — | — |
| Shareholders' equity | $151.01M | $168.80M | $257.46M | $231.64M | $270.66M | $357.72M |
| Shares outstanding | 35.90M | 35.39M | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$17.05M | -$31.92M | -$32.56M | -$30.69M | -$38.64M | -$45.01M |
| Capital expenditure | $0 | $25,000 | $17,000 | $12,000 | $39,000 | $35,000 |
| Free cash flow | -$17.05M | -$31.94M | -$32.58M | -$30.70M | -$38.68M | -$45.04M |
| Investing cash flow | $0 | -$25,000 | $34.98M | $103.28M | $36.40M | $14.85M |
| Financing cash flow | $4.66M | -$48.51M | $7.85M | -$7.06M | -$52.10M | $5.72M |
| Depreciation & amortization | $92,000 | $105,000 | $125,000 | $140,000 | $142,000 | $146,000 |
| Stock-based compensation | $8.90M | $8.32M | $11.50M | $9.85M | $7.66M | $7.75M |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.